-
肺癌是一种恶性程度极高且易复发、转移的恶性肿瘤,患者的病死率无论在男性还是女性患者中均占恶性肿瘤的第一位[1]。基于其生物学特性、临床治疗及预后特点,肺癌可分为两大类:非小细胞肺癌(non-small cell lung cancer, NSCLC)和小细胞肺癌(small cell lung carcinoma, SCLC)。PET与CT融合后,对肺癌诊断和疗效评价的敏感性和准确性大大提高[2]。近年来,PET-CT在肺癌中的临床应用价值已经得到肯定,可以在肺癌早期评估肺癌患者化疗后疗效,同时建立有效的系统辅助治疗措施,提高肺癌患者的生存质量和生存率[3-4]。
18F-FDG PET-CT在评价肺癌化疗疗效中的应用
The application of 18F-FDG PET-CT in evaluation of the value of lung cancer chemotherapy
-
摘要: 肺癌是全世界目前最常见的因肿瘤致死的原因之一,化疗是治疗晚期非小细胞肺癌(NSCLC)及小细胞肺癌(SCLC)的主要手段,且近年来已逐渐应用于NSCLC的早期和中期阶段的治疗。随着新技术的发展,18F-FDG PET-CT逐渐应用于肺癌患者的化疗疗效和预后评价中,该文综述了18FDG PET-CT在肺癌化疗中的应用。
-
关键词:
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 癌,非小细胞肺 /
- 癌,小细胞 /
- 氟脱氧葡萄糖F18 /
- 药物疗法
Abstract: Lung cancer has become the leading cause of cancer-related death in the world, chemotherapy plays an important role in the treatment of advanced non-small cell lung cancer (NSCLC) and small cell lung carcinoma(SCLC), and now is gradually applied in the early and middle stage of NSCLC. With the development of new technology, 18F-FDG PET-CT is applied in evaluation of chemotherapy effect and prognosis in patients with lung cancer. The application of 18F-FDG PET-CT in the lung cancer chemotherapy are reviewed in this paper. -
[1] Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin, 2008, 58(2): 71-96. doi: 10.3322/CA.2007.0010 [2] 宋平平, 贾慧, 张百江. FDG-PET及PET-CT在肺癌中的应用价值. 肿瘤防治杂志, 2004, 11 (1): 103-106. doi: 10.3969/j.issn.1673-5269.2004.01.034
[3] 张晓颖, 韩冰, 侯跃芳, 等. 非小细胞肺癌淋巴结分期的PET/CT准确性评价——Meta分析. 中国临床医学影像杂志, 2009, 20(3): 184-188. doi: 10.3969/j.issn.1008-1062.2009.03.009
[4] 于丽娟, 锻玉, 梁秀艳, 等. 18F-FDG PET/CT显像在肺癌诊断及探查转移灶中的价值. 中国医学影像技术, 2007, 23(4): 605-607.
[5] Martini N, Kris MG, Flehinger BJ, et al. Preoperative chemotherapy for stage Ⅲa (N2) lung cancer: the Sloan-Kettering experience with 136 patients. Ann Thorac Surg, 1993, 55(6): 1365-1373. doi: 10.1016/0003-4975(93)91072-U [6] Ryu JS, Choi NC, Fischman AJ, et al. FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradio-stherapy: correlation with histopathology. Lung Cancer, 2002, 35(2): 179-187. doi: 10.1016/S0169-5002(01)00332-4 [7] Santo A, Genestreti G, Sava T, et al. Neo-adjuvant chemotherapy in non-small cell lung cancer(NSCLC). Ann Oncol, 2006, 17(Suppl 5): v55-v61. [8] Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomog-raphy is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol, 2003, 21(7): 1285-1292. doi: 10.1200/JCO.2003.07.054 [9] Hoekstra CJ, Stroobants SG, Smit EF, et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol, 2005, 23(33): 8362-8370. doi: 10.1200/JCO.2005.01.1189 [10] Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Potential use of FDG-PET scan after induction chemotherapy in surgically staged Ⅲ a-N2 non-small-cell lung cancer: a prospective pilot study. The Leuven Lung Cancer Group. Ann Oncol, 1998, 9(11): 1193-1198. [11] Cerfolio RJ, Bryant AS, Winokur TS, et al. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer. Ann Thorac Surg, 2004, 78(6): 1903-1909 doi: 10.1016/j.athoracsur.2004.06.102 [12] Rivera MP. Multimodality therapy in the treatment of lung cancer. Semin Respir Crit Care Med, 2004, 25(Suppl 1): 3-10. [13] Weber WA, Petersen V, Schmidt B, et al. Positron emission tomogra-phy in non small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol, 2003, 21(14): 2651-2657. doi: 10.1200/JCO.2003.12.004 [14] Pöttgen C, Lecegrün S, Theegarten D, et al. Value of 18F-fluoro-2-de-oxy-D-glucose-positron emission tomography/ computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res, 2006, 12(1): 97-106. doi: 10.1158/1078-0432.CCR-05-0510 [15] Goffin J, Baral S, Tu D, et al. Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval. Clin Cancer Res, 2005, 11(16): 5928-5934. doi: 10.1158/1078-0432.CCR-05-0130 [16] van den Boogaart V, de Langen A, Groen HJ, et al. A phase Ⅱ study of erlotinib (E) and bevacizumab (B) in chemo naive patients (pts) with locally advanced or metastatic non small cell lung cancer (NSCLC): Predictive value of molecular imaging. J Clin Oncol, 2008, 26(15s): 8055. [17] Yamamoto Y, Kameyama R, Murota M, et al. Early assessment of thera-peutic response using FDG PET in small cell lung cancer. Mol Imaging Biol, 2009, 11(6): 467-472. doi: 10.1007/s11307-009-0227-y [18] Fischer BM, Mortensen J, Langer SW, et al. PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer, 2006, 54(1): 41-49. doi: 10.1016/j.lungcan.2006.06.012 [19] Spaepen K, Stroobants S, Dupont P, et al. [18F]FDG PET monitoring of tumour response to chemotherapy: does[18F]FDG uptake correlate with the viable tumour cell fraction. Eur J Nucl Med Mol Imaging, 2003, 30(5): 682-688. doi: 10.1007/s00259-003-1120-6 [20] Boellaard R, Oyen WJ, Hoekstra CJ, et al. The Netherlands protocol for standardisation of FDG whole body PET studies in multi-center trials. Eur J Nucl Med Mol Imaging, 2008, 35(12): 2320-2333. doi: 10.1007/s00259-008-0874-2 [21] Minn H, Zasadny KR, Quint LE, et al. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-D-glucose uptake at PET. Radiology, 1995, 196 (1): 167-173. doi: 10.1148/radiology.196.1.7784562 [22] Weber WA, Ziegler SI, Thödtmann R, et al. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med, 1999, 40 (11): 1771-1777. [23] Port JL, Kent MS, Korst RJ, et al. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg, 2004, 77(1): 254-259. doi: 10.1016/S0003-4975(03)01457-7
计量
- 文章访问数: 902
- HTML全文浏览量: 487
- PDF下载量: 1